GUIDEWIRE
23.3.2022 07:02:05 CET | Business Wire | Press release
Guidewire (NYSE: GWRE) today announced that it has opened its new EMEA headquarters 10 years after the company opened its first office in Dublin. Based in Blanchardstown, the new office building occupies 85,000ft² and is evidence of Guidewire’s continued commitment to Ireland and its customers across Europe. Adapting to the new world of work, Guidewire is offering employees fully remote and hyperflexible working practices. As well as providing employees with a state-of-the-art work environment, the office also includes an executive briefing centre for its customer and partner community across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006033/en/
Since 2011, Guidewire’s Dublin base has grown to become the company’s largest employee community in Europe and outside of the USA, including a diverse range of 35+ nationalities. Guidewire anticipates scaling headcount by about 150 new recruits to around 600 staff over the next two to three years and is actively hiring across a range of positions, from entry-level graduate roles to business analysts, cloud operations, consulting managers, engineering, HR & Recruitment, project managers, specialist cloud transition roles, and technology consultants.
Since 2016 Guidewire Dublin has made the top 20 in the Great Place to Work, including 10th place in Ireland’s Best Workplaces 2021 for best large company.
“This is an exciting moment for Guidewire in Ireland as we open our new EMEA HQ, reflecting the enormous contribution of our team to the Guidewire corporate and customer community,” said Niall Lalor, Ireland country manager, Guidewire. “As the company has grown and evolved over the past 10 years in Ireland, I’m hugely proud that we have retained our strong sense of identity and close-knit culture throughout. We’ve still only scratched the surface and look forward to growing our talented team even more across the country, with Guidewire in Dublin well placed as a hub for innovation that supports our business both in EMEA and globally.”
The Irish operations include Customer & Cloud Operations, Delivery Services, and Product Development, with teams that have spearheaded Guidewire’s digital products, created specific local solutions for European customers, as well as managed the implementations and support of the company’s first cloud customers. The siting of the cloud team in Dublin also takes advantage of access to top new graduates from Ireland, the wider European Union, and beyond.
“Ireland has been central to Guidewire’s international growth over the past 10 years,” said Mike Rosenbaum, chief executive officer, Guidewire. “It’s nothing new to say that the world has witnessed extraordinary changes over the past two years and the insurance industry is no exception. Guidewire continues to be an indispensable partner to our 450+ customers around the world. Guidewire aspires to design, build, and run a mission critical cloud service, and our team in Ireland is critical to making this a reality.”
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said “I’m so pleased Guidewire has chosen Blanchardstown for its new EMEA headquarters. Guidewire is a leading player in the software industry and this expansion, which will create an additional 150 highly skilled jobs, demonstrates the company’s continued commitment to Ireland after 10 years. I wish the team every success with their expansion plans.”
Commenting on the news Mary Buckley, Executive Director, IDA Ireland, said “Today’s announcement demonstrates Guidewire’s continued confidence in the availability of a highly skilled and talented workforce in Ireland to further support its evolution and to deliver on its strategic corporate goals. I wish the team continued success in their new office building and offer the company the ongoing support of IDA Ireland.”
Further details are available at: https://careers.guidewire.com/location/dublin
Dublin office video:
https://players.brightcove.net/929656735001/41G8Cuaute_default/index.html?videoId=6300984518001
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localisation, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
